HAPPY EASTER! 50% Off Premium Subscription Claim Offer ⏰ 0d 00h 00m 00s

Blueprint Medicines Earnings Calls

Q1 2025 (Upcoming)
Release date May 01, 2025
EPS estimate -$0.410
EPS actual -
Revenue estimate 158.093M
Revenue actual -
Expected change +/- 10.39%
Q4 2024 Missed
-$0.790 (-16.18%)
Release date Feb 13, 2025
EPS estimate -$0.680
EPS actual -$0.790
EPS Surprise -16.18%
Revenue estimate 158.443M
Revenue actual 146.366M
Revenue Surprise -7.62%
Q3 2024 Beat
-$0.89 (8.25%)
Release date Oct 30, 2024
EPS estimate -$0.97
EPS actual -$0.89
EPS Surprise 8.25%
Revenue estimate 146.6M
Revenue actual 128.184M
Revenue Surprise -12.56%
Q2 2024 Beat
-$0.80 (37.50%)
Release date Aug 01, 2024
EPS estimate -$1.28
EPS actual -$0.80
EPS Surprise 37.50%
Revenue estimate 103.57M
Revenue actual 138.157M
Revenue Surprise 33.39%

Last 4 Quarters for Blueprint Medicines

Below you can see how BPMC performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

Q2 2024 Beat
Release date Aug 01, 2024
Fiscal end date Jun 30, 2024
Price on release $100.29
EPS estimate -$1.28
EPS actual -$0.80
EPS surprise 37.50%
Date Price
Jul 26, 2024 $112.19
Jul 29, 2024 $110.34
Jul 30, 2024 $107.03
Jul 31, 2024 $108.30
Aug 01, 2024 $100.29
Aug 02, 2024 $96.72
Aug 05, 2024 $92.97
Aug 06, 2024 $92.74
Aug 07, 2024 $90.85
4 days before -10.61%
4 days after -9.41%
On release day -3.56%
Change in period -19.02%
Q3 2024 Beat
Release date Oct 30, 2024
Fiscal end date Sep 30, 2024
Price on release $89.24
EPS estimate -$0.97
EPS actual -$0.89
EPS surprise 8.25%
Date Price
Oct 24, 2024 $83.09
Oct 25, 2024 $82.47
Oct 28, 2024 $82.77
Oct 29, 2024 $83.40
Oct 30, 2024 $89.24
Oct 31, 2024 $87.51
Nov 01, 2024 $90.70
Nov 04, 2024 $91.88
Nov 05, 2024 $97.55
4 days before 7.40%
4 days after 9.31%
On release day -1.94%
Change in period 17.40%
Q4 2024 Missed
Release date Feb 13, 2025
Fiscal end date Dec 31, 2024
Price on release $95.19
EPS estimate -$0.680
EPS actual -$0.790
EPS surprise -16.18%
Date Price
Feb 07, 2025 $105.71
Feb 10, 2025 $104.00
Feb 11, 2025 $101.57
Feb 12, 2025 $103.56
Feb 13, 2025 $95.19
Feb 14, 2025 $93.94
Feb 18, 2025 $92.48
Feb 19, 2025 $94.07
Feb 20, 2025 $94.35
4 days before -9.95%
4 days after -0.88%
On release day -1.31%
Change in period -10.75%
Q1 2025 (Upcoming)
Release date May 01, 2025
Fiscal end date Mar 30, 2025
Price on release -
EPS estimate -$0.410
EPS actual -
Date Price
Apr 11, 2025 $80.84
Apr 14, 2025 $82.53
Apr 15, 2025 $81.45
Apr 16, 2025 $82.11
Apr 17, 2025 $84.71

Blueprint Medicines Earnings Call Transcript Summary of Q4 2024

Strong Financial Performance:

FY 2024 product revenue reached $479 million, marking a remarkable growth of 135% year-over-year.

  • AYVAKIT, the company’s flagship product for systemic mastocytosis (SM), is projected to generate $680 million to $710 million in 2025, with a midpoint growth rate of 45%.

Market Potential and Growth Drivers:

  • Current penetration of AYVAKIT among diagnosed patients is less than 10%, indicating significant growth potential.
  • The total diagnosed SM patient pool is estimated to be around 60,000 in the U.S., double previous estimates. Awareness and diagnosis efforts have led to consistent double-digit growth over the last five years.
  • The SM franchise is now projected to peak at a value of $4 billion, anchored by AYVAKIT.

Investment and Strategic Expansion:

  • Blueprint will increase investments in education, commercial infrastructure, and market-building initiatives to capitalize on growth opportunities.
  • Plans are underway to expand educational outreach to more healthcare providers, including medical dermatologists and gastroenterologists, who can help diagnose and treat SM.

Product Development Pipeline:

  • The development of elenestinib, a next-generation KIT D816V inhibitor, is in Phase III trials, focusing on disease modification rather than just symptom control.
  • Initiatives for BLU-808, a next-generation KIT inhibitor, involve proof-of-concept studies set to start in 2025 for various allergic and inflammatory diseases.

Financial Discipline:

  • Operating cash burn was significantly reduced in 2024, and is expected to further decline in 2025.
  • The company entered 2025 with a healthy cash position of $864 million, with additional cash anticipated from GSK's acquisition of IDRx.

Long-term Outlook:

  • Blueprint Medicines is positioned to grow significantly with operating excellence, a unique product portfolio, and an expanding market opportunity in the mast cell biology space.
  • The guidance of $2 billion in revenue by 2030 reflects confidence in continued penetration into the SM market, with expectations set for ongoing growth beyond that target.

Key Considerations for Investors:

  • Blueprint Medicines is in a strong growth trajectory with a well-defined strategy to expand into new markets and specialties.
  • The company’s proactive investments in medical education and commercial infrastructure support its revenue projections.
  • Focus on value creation with multiyear commercial potential, especially in light of a significant underserved patient population.
  • Continuous monitoring of AYVAKIT’s penetration, competition dynamics, and progress in clinical trials will be critical to evaluating the company's future performance and stock value.

Blueprint Medicines Earnings History

Earnings Calendar

FAQ

When is the earnings report for BPMC?
Blueprint Medicines Corporation (BPMC) has scheduled its earnings report for May 01, 2025 before the markets open.

What is the BPMC price-to-earnings (P/E) ratio?
BPMC P/E ratio as of Apr 17, 2025 (TTM) is -77.25.

What is the BPMC EPS forecast?
The forecasted EPS (Earnings Per Share) for Blueprint Medicines Corporation (BPMC) for the first fiscal quarter 2025 is -$0.410.

What are Blueprint Medicines Corporation's retained earnings?
On its balance sheet, Blueprint Medicines Corporation reported retained earnings of $146.37 million for the latest quarter ending Dec 31, 2024.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT BLUEPRINT MEDICINES CORPORATION
Blueprint Medicines
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally avail...
GOLDEN STAR
Ticker Change Signal Date
F
FNA
$12.99
0.85% Apr 15
V
VCSH
$78.34
0.370% Apr 15
F
FTSM
$59.85
0.117% Apr 15
S
SLQD
$49.97
0.260% Apr 15
I
ISTB
$48.11
0.239% Apr 15

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE